# CJC-1295 Ipamorelin Research: Mechanism, Synergy, and the Clinical Record > CJC-1295 Ipamorelin research: the dual-receptor mechanism, the GHRH-plus-GHRP synergy evidence, the human GH/IGF-1 kinetics, and the limits of the data — fully cited. From the GHRH and ghrelin pathways to the human pharmacodynamics — mechanism first, every number attributed. ## Start here The CJC-1295 Ipamorelin research splits cleanly into three layers, and keeping them apart is the whole point. The first layer is mechanism: how two peptides hit two different receptors on one pituitary cell to release more growth hormone (GH) together than apart. The second is the single-component human data: how much, and for how long, each half moves GH and IGF-1. The third is the gap: the fixed blend itself has never been tested in a clinical trial, so its combined human profile is inferred, not measured. In plain English: the parts are well studied, the synergy idea is well supported by older human work using related peptides, and the specific mixture sold as "CJC-1295 Ipamorelin" is not. This page walks all three layers, marking which claims rest on direct measurement and which rest on read-across. Every fold-change, half-life, and dose below is tied to a numbered source. ## The dual-receptor mechanism CJC-1295 and ipamorelin converge on the somatotroph — the anterior-pituitary cell that makes and secretes GH — through two independent receptors. CJC-1295 binds the GHRH receptor (GHRH-R), a class-B G-protein-coupled receptor coupled to Gs. Activation raises cyclic AMP (cAMP), the cell's second-messenger "go" signal, which drives PKA, then CREB, then transcription and release of GH. Ipamorelin binds GHS-R1a, the ghrelin receptor, coupled to Gq; activation runs through phospholipase C and IP3 to release intracellular calcium, which forces GH granules to empty. The ghrelin arm also blunts somatostatin — the body's brake on GH — adding a second push. Because the two arms use separate signaling chemistry that meets at the same endpoint, co-stimulation is supra-additive: the combined GH pulse exceeds the sum of the parts. The downstream consequence is hepatic IGF-1 synthesis, which carries out much of GH's anabolic and lipolytic action while feeding back to restrain the axis. A 2025 receptor-signalling review underpins the GHRH-R side of this mechanism [13]. ## Cjc-1295 ipamorelin: the synergy evidence The case for combining a GHRH analogue with a GHRP is older than either of these specific peptides. In 18 normal adult men, submaximal GH-releasing peptide doses (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically, the two acting through independent mechanisms [3]. This is the foundational human evidence that a GHRP-plus-GHRH combination produces supra-additive GH release — the direct mechanistic rationale for the cjc-1295 ipamorelin pairing. The receptor-level confirmation came in 2002: co-activating cloned GHS and GHRH receptors in transfected HeLa cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, pointing to direct receptor cross-talk [4]. Together these two studies are why the pairing exists — though both used related peptides and model systems, not the fixed CJC-1295 + ipamorelin blend. ## Ipamorelin cjc 1295: what each half contributes The ipamorelin cjc 1295 pairing is deliberately complementary. Ipamorelin (a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2) is the first selective GH secretagogue: unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses more than 200 times the ED50 for GH release, while matching GHRP-6's GH efficacy in swine (ED50 2.3 nmol/kg) [2]. That selectivity — GH without the stress-hormone spillover — is the property that made it attractive for stacking. The CJC-1295 half supplies duration. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults; after multiple doses, IGF-1 remained above baseline for up to 28 days [1]. So ipamorelin contributes a clean, sharp pulse and CJC-1295 contributes a multi-day GHRH background — at least in theory, since the combined profile has never been measured directly. ## Cjc 1295 and ipamorelin: the human pharmacodynamics The most reassuring single finding on the cjc 1295 and ipamorelin axis concerns pulsatility. During continuous CJC-1295 stimulation in healthy men, pulsatile GH secretion persisted: pulse frequency and amplitude were unaltered while basal (trough) GH rose about 7.5-fold, producing a 46% rise in mean GH and a 45% rise in IGF-1 at 60 or 90 µg/kg [9]. Continuous GHRH-R drive raised the GH floor without abolishing the physiologic rhythm — a key pharmacodynamic point for any GHRH-analogue protocol. For context on how the body itself regulates this rhythm, a 5-day fast in men raised GH pulse frequency from 5.8 to 9.9 pulses per 24 hours and increased 24-hour GH concentration [10] — the endogenous baseline the combination aims to amplify. The DAC chemistry that makes the CJC-1295 background possible is detailed on the [cjc 1295 dac](/cjc-1295-dac) page. ## Cjc ipamorelin: class-level and read-across evidence Beyond the GH axis, the cjc ipamorelin literature draws on class-level data for the ghrelin-receptor arm. The synthetic ghrelin-receptor agonist TZP-101 (0.03–1 mg/kg IV), structurally related to ipamorelin's class, dose-dependently improved gastrointestinal transit in a rat model of postoperative ileus, decreasing time to first bowel movement and increasing fecal output [11], with prokinetic effects more pronounced in the stomach than the small intestine across surgery-, morphine-, and combined-induced ileus [12]. These establish class-level evidence that ghrelin agonists restore bowel function after surgery — the therapeutic rationale behind ipamorelin's own (unapproved) postoperative-ileus program. For the GHRH arm, the freshest high-quality read-across comes from a related analogue: a 2026 meta-analysis of 5 randomized controlled trials of the GHRH analogue tesamorelin found significant reductions in visceral adipose tissue (−27.71 cm²) and hepatic fat (−4.28%), increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or glucose perturbation [7]. It shows that GHRH-analogue stimulation of the GH/IGF-1 axis can drive visceral- and hepatic-fat reduction with a manageable profile — read-across context for the GHRH arm, not evidence for the blend. A 2024 study also found ipamorelin acetate activated the hypothalamic-pituitary-gonadal axis in fish, elevating LH and 11-ketotestosterone [14], a cross-species signal of broader ghrelin-receptor activity. ## The receptor cross-talk question One open mechanistic question is whether the GHRH and ghrelin arms interact at the receptor itself or only at the level of GH output. The HeLa co-transfection data suggest direct cross-talk: ghrelin and GH secretagogues potentiated GHRH-induced cAMP production in cells expressing both receptors, beyond what either stimulus produced alone [4]. Whether that receptor-level potentiation fully accounts for the in-vivo synergy [3], or whether the somatostatin-antagonism of the ghrelin arm is the larger driver, has not been resolved for this specific pairing. What the literature does not contain is a controlled human study of the fixed CJC-1295 + ipamorelin blend measuring its combined GH/IGF-1 output, its pharmacokinetics, or its safety. That absence is not a footnote — it is the reason every efficacy statement on this site is carefully attributed to single-component or general-synergy data rather than to "the blend." --- A mechanism-first reading of the CJC-1295 and ipamorelin record — two receptors, two timescales, every figure logged to its study and the untested fixed blend kept in plain view; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.